Opinion

Video

First-Line Therapy for Chronic GvHD

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Related Videos
Elizabeth Buchbinder, MD
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Related Content
Acute Myeloid Leukemia | stock.adobe.com
December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML